HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Globalization Act of 2009

This article was originally published in The Rose Sheet

Executive Summary

Rep John Dingell, D-Mich., former Energy and Commerce Committee chairman, has revived his proposal for sweeping regulatory and import safety reforms amid a recent flurry of recalls related to salmonella-contaminated peanut butter, according to a Jan. 28 release. Although the latest food contamination outbreak - which has sickened nearly 500 people and been linked to eight deaths - is emphasized most in the sponsors' remarks, the bill seeks to equip FDA with appropriate funding and authority for regulating not only food but drugs, devices and cosmetics as well. Similar to the version that circulated in draft form in 2008, the bill would require cosmetic manufacturers to register their facilities with FDA, submit ingredient statements and report serious and unexpected adverse events (1"The Rose Sheet" April 21, 2008, p. 4). Rep. Frank Pallone, D-N.J., chairman of the Health subcommittee and a recognized ally of the dietary supplement industry, and Dingell protégé Rep. Bart Stupak, D- Mich., who chairs the Oversight and Investigations subcommittee, are co-sponsors of the bill. While some experts believe the focus of the 111 Congress will be on economic and health-care issues, "the fact that Dingell, Stupak and Pallone are all on the bill means that this is a top priority," according to John Manthei, a food and drug attorney at Latham & Watkins and former Energy and Commerce majority counsel
Advertisement

Related Content

Obama Wants FDA’s “Full Review” As Recall Of Peanut Butter Items Goes On
Beauty Firms Face Adverse Event Reporting, GMP Requirements Under Bill
Beauty Firms Face Adverse Event Reporting, GMP Requirements Under Bill
Advertisement
UsernamePublicRestriction

Register

RS015933

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel